Huaitian Liu

1 month ago | biorxiv.org | Sanna Madan |Tiangen Chang |Alexandra Harris |Huaitian Liu

AbstractChimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies. However, its application in solid tumors remains limited because single targets are unlikely to suffice due to tumor antigen heterogeneity and off-tumor toxicities.